Healthcare Private Placement and M&A Transactions Review Week Ending August 7 2022

Strategy | Financing Highlight
“Three to five years ago, the big strategics were sprinkling money around, but you are now seeing more focus from them,” said Jonathan Hodson-Walker, managing partner of Silverwood Partners, an investment banking firm that advises CPG brands. “The strategics are still making minority investments, but they are less interested in buying small brands that are experimental and can’t be $100M businesses. Supply chains and scale are very important to them right now.”
Silverwood Partners Features in Organic Insider – Read the article
here

Private Placement / Financing Transactions

F2G: The company raised $70 million of venture funding in a deal led by Forbion and Sofinnova Partners on August 4, 2022. Advent Life Sciences, Novo Holdings, Morningside Group, and Cowen Healthcare Investments also participated in the round. The company is a developer of a biotech drug designed to treat life-threatening invasive fungal infections with novel therapies.

Atia Vision: The company raised $42 million of Series E venture funding in a deal led by Cormorant Asset Management on August 2, 2022. The Capital Partnership, PA MedTech VC Fund, AMED Ventures, and Shifamed also participated in the round. The company is a developer of presbyopia-correcting medical devices designed to provide accommodating intraocular lenses.

Annexus Health: The company raised $33 million through a combination of Series B-1 and Series B-2 venture funding in a deal led by Transformation Capital on August 2, 2022, putting the company’s pre-money valuation at $97 million. The company is an operator of a healthcare technology company intended to reduce administrative burdens across the patient lifecycle.

Sibel Health: The company raised $33 million of Series B venture funding in a deal led by Steele Foundation for Hope on August 4, 2022. Drägerwerk also participated in the round. The company is a developer of a medical device designed to offer wireless vital sign monitoring to patients and pregnant mothers.

Medici: The company announced it will raise $30 million of an undisclosed targeted amount of venture funding on August 1, 2022. The company is a developer of a telemedicine platform designed to connect healthcare providers with their patients from anywhere at any time.

Cellanome: The company raised $30 million of venture funding from undisclosed investors on August 4, 2022. The company is a developer of a multiomics platform designed to measure biology at an unprecedented resolution and scale.

Vitara: The company raised $25 million of venture funding from Flerie Invest & undisclosed investors on August 2, 2022. The company is a developer of a therapeutic platform intended to support premature infants.

GT Metabolic: The company raised an estimated $20.2 million through a combination of Series A and Series A-1 venture funding from Ceros Financial Services, HealthTech Capital and other undisclosed investors on August 2, 2022, putting the company’s pre-money valuation at $40 million. The company is a developer of medical technology for gastric bypass.

CareHarmony: The company raised $15 million of venture funding from undisclosed investors on August 4, 2022. The company is a developer of a chronic care management platform designed to help healthcare providers improve the patient experience and clinical outcomes.

Atropos Health: The company raised $14 million of Series A venture funding in a deal led by Breyer Capital on August 4, 2022. Boston Millennia Partners and Emerson Collective also participated in the round. The company is a developer of a clinical analytics platform designed to transform health data into usable real-world evidence.

Immunis: The company raised $10 million of Series A venture funding in a deal led by Remiges Ventures on August 3, 2022. Other undisclosed investors also participated in the round. The company is a developer of stem cell-derived therapy designed to treat age and disease-related immune decline.

Maximus Health: The company raised $9.1 million of venture funding from undisclosed investors on August 3, 2022. The company is an operator of a consumer health business based in Santa Monica, California.

Haermonics: The company raised $4.3 million of Series A venture funding from Demcon, Brabantse Ontwikkelings Maatschappij and NLC on August 2, 2022. The company is a developer of a postoperative surgical drainage technology designed to offer clean and safe open-heart surgery.

Exothera: The company raised an undisclosed amount of venture funding from SambrInvest in August 2022. The company is a provider of contract manufacturing and development services intended to design and deliver affordable viral vector-based vaccines and cell and gene therapies.

Ostiio: The company raised an undisclosed amount of venture funding from Lontra Ventures in August 2022. The company is a developer of a bone distraction system designed to correct skeletal deformities and deficiencies.

M&A Transactions

Chemocentryx / Amgen: The company reached a definitive agreement to be acquired by Amgen for $4 billion on August 4, 2022. ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer.

MiroBio / Gilead Sciences: The company reached a definitive agreement to be acquired by Gilead Sciences for $405 million on August 4, 2022. The company is a developer of novel therapeutics technology designed to bring significant benefits to patients suffering from a range of auto-immune diseases.

IPG / Evolent Health: The company was acquired by Evolent Health for $375 million on August 1, 2022. The company is a provider of surgical cost management services intended to reduce surgical and implant procedure expenses.

Exact Sciences / MDxHealth: The Oncotype DX GPS Prostate Cancer Business was acquired by MDxHealth through a $100 million on Aug 2, 2022. The company is a provider of broadly commercialized and clinically validated tests available today across the urology community.

BioRez / Conmed: The company reached a definitive agreement to be acquired by Conmed for $85 million on August 1, 2022. The company is a developer of bio-inductive implants designed to harness the body’s regenerative capacity to rebuild functional tissue and improve musculoskeletal outcomes.

Tetris Pharma / Arecor: The company reached a definitive agreement to be acquired by Arecor for GBP 6 million on August 1, 2022. The company is an operator of a pharmaceutical company focused on developing and acquiring niche injectable and topical products.

KetaMD / Braxia Scientific: The company was acquired by Braxia Scientific for $6 million on August 3, 2022. The company is a developer of a telemedicine platform designed to tackle stress, anxiety, depression, PTSD, mood disorders and pain.

Connor B. Judge Foundation / The Sumaira Foundation: The company was acquired by The Sumaira Foundation for an undisclosed amount on August 4, 2022. The company is a provider of awareness and research funds intended for neuromyelitis optica (NMO) and other autoimmune diseases.

Glacial Lakes Orthopaedics / Prairie Lakes Healthcare System: The company was acquired by Prairie Lakes Healthcare System for an undisclosed amount on August 1, 2022. The company is a provider of orthopedic treatments based in Watertown, South Dakota.

Iontox / LifeNet Health: The company was acquired by LifeNet Health for an undisclosed amount on August 1, 2022. The company is a developer of a biotechnology platform intended to provide multiple organ test systems and in-vitro toxicology-based consultancy services.

Mementor / ResMed: The company was acquired by ResMed for an undisclosed amount on August 1, 2022. The company is a developer of digital health applications designed for the field of sleep medicine.

Varinos / Mitsubishi UFJ Securities Holdings: The company was acquired by Mitsubishi UFJ Securities Holdings for an undisclosed amount on August 3, 2022. The company is a developer of genome analysis technology intended to provide contract testing and analysis services.

Categories

Archives